查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1931176

婴幼儿退烧药市场依剂型、活性成分、给药途径及通路划分，全球预测（2026-2032年）

Antipyretic Medicine for Infants & Young Children Market by Dosage Form, Active Ingredient, Administration Route, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，婴幼儿退烧药市值为 4.8897 亿美元，预计到 2026 年将成长至 5.107 亿美元，年复合成长率为 5.67%，到 2032 年将达到 7.1977 亿美元。

关键市场统计数据
基准年 2025 4.8897亿美元
预计年份：2026年 5.107亿美元
预测年份 2032 7.1977亿美元
复合年增长率 (%) 5.67%

一份全面的儿童退烧治疗指南，整合了临床安全性、看护者行为、製剂进度和监管趋势，旨在帮助做出明智的决策。

要全面了解婴幼儿退烧药的现状，需要从多个方面进行介绍，将临床考量、看护者行为、法律规范以及供应链实际情况整合到一个统一的框架中。本报告首先阐明了儿童退烧治疗的目标，重点强调了安全性、剂量准确性和看护者从性这三个影响产品设计和传播策略的核心要素。除了临床实践之外，本报告还着重介绍了製剂科学在提高偏好和改善弱势群体用药准确性方面的作用，并强调了製剂选择对照看护者接受度和用药依从性的影响。

重大的结构和技术变革将重新定义儿童退烧药的产品、分销、监管以及看护者在临床和商业方面的参与。

退烧药领域正经历重大变革，这些变革正在改变婴幼儿产品的研发、监管和分销方式。其中一个显着的变化是配方创新与看护者为中心的设计理念的融合。製造商优先考虑易于服用的剂型和更佳的偏好，同时投资改进包装和提高剂量准确性，以减少用药错误。与这些产品层面的变革相呼应的是技术主导的转型，例如数位化用药指导和远端医疗的整合，这些变革正在改变看护者获取指导的方式以及临床医生远端监测发热管理的方式。

2025年关税环境对儿童退烧药供应链的采购、生产柔软性、监管合规性和商业策略的影响

美国当局于2025年推出的定向关税对婴幼儿退烧药的生产商、经销商和购买者产生了多方面的影响。关税带来的成本压力促使企业重新评估其供应链布局，一些企业正在探索近岸外包方案，并重新谈判供应商合同，以在不损害产品完整性或儿童安全标准的前提下维持毛利率。同时，进口关税的变化也加速了从不同供应商购买原料药以及加强库存缓衝以缓解暂时性成本波动的讨论。

基于详细的细分，将临床和商业性重点与剂型、活性成分、给药途径、分销管道和年龄组联繫起来，提供洞察。

关键细分市场分析揭示了产品属性、活性成分、给药途径、通路以及特定年龄层的需求如何影响婴幼儿退烧药的临床效用和商业性吸引力。按剂型划分，市场包括滴剂、悬浮液、糖浆和片剂，每种剂型在剂量准确性、看护者接受度和包装技术方面都有其独特的考虑因素。基于活性成分的分析表明，Ibuprofen和乙酰胺酚是关键成分。这些成分的起效时间、给药间隔和耐受性各不相同，这会影响用药决策和看护者指导。基于给药途径的分析强调了口服和直肠给药在临床和情境中发挥不同的作用，这有助于产品定位，尤其是在术后和催吐等情况下。

区域法规结构、流通结构和看护者偏好如何影响美洲、欧洲、中东和非洲以及亚太地区的儿童退烧策略

区域趋势对婴幼儿退烧药的法规结构、供应链结构以及看护者的偏好有显着影响。在美洲，分销基础设施结合了完善的零售药局网路和不断扩展的线上配送能力，监管机构也更加重视儿童标籤的清晰度和上市后安全性监测。这种环境有利于那些拥有可靠的儿童安全性数据、包装便于在家准确用药，以及能够与医疗机构合作将药品纳入医保目录并开展专业教育的产品。

儿童退烧药：竞争优势源自于配方创新、儿童安全信誉、供应链合作与全通路策略

婴幼儿退烧药市场的竞争趋势取决于製剂技术、儿童安全认证、供应链韧性和通路伙伴关係等因素的综合作用。领先的竞争对手透过专注于剂量准确性和便于看护者使用的剂型，以及对临床证据和上市后监测的定向投资，来维持专家的信任。差异化越来越依赖将临床适用的活性成分与包装创新相结合的能力，从而减少剂量错误并改善偏好，进而提高敏感年龄层儿童的用药依从性。

为成功开发儿童退烧药，需制定一项切实可行的策略，将配方创新、供应弹性、证据产生和通路特定商业化结合。

有意掌握婴幼儿退烧药市场机会的产业领导者应优先考虑切实可行的措施，兼顾临床价值与商业性和营运效率。首先，投资配方和包装创新，优先考虑剂量精准性和偏好，并确保这些改进得到透明的安全资讯和看护者教育材料的支持。其次，增加供应商多样性，实现灵活的生产方式，以降低关税和贸易中断带来的风险，同时加强可追溯性和文件记录，以确保符合法规要求。

一项采用综合方法、结合专家访谈、临床文献综述、市场細項分析和供应链情境评估的严谨混合研究，得出了可靠的研究结果。

本报告的调查方法结合了定性和定量技术，旨在对儿童退烧药物的发展趋势进行严谨且可靠的分析，同时兼顾临床和监管方面的限制。主要研究包括对小儿科医生、製剂科学家、采购人员和通路经理进行结构化检验和咨询，以收集关于给药实践、产品选择标准和物流挑战等方面的实际观点。此外，还对二级资讯来源进行了综合分析，透过对官方监管指南、产品专论和临床文献检验，确保研究结果符合当前的最佳实践和安全标准。

整合临床、营运和区域性需求，凸显了确保儿童安全、供应连续性和解热商业性市场差异化发展的策略。

总之，婴幼儿退烧药市场处于临床需求、看护者期望、法律规范以及不断演变的分销模式的交汇点。产品成功取决于儿童安全证据与看护者能够可靠使用的实用给药方案之间的清晰契合。同时，供应链韧性和考虑​​关税的筹资策略已成为影响产品供应和商业性柔软性的核心策略重点。区域差异进一步加剧了竞争格局的复杂性，需要根据各地区的医疗保健体系和消费行为制定量身定制的监管措施和分销策略。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：婴幼儿退烧药市场（依剂型划分）

  • 滴
  • 悬浮液
  • 糖浆
  • 药片

第九章 依活性成分分類的婴幼儿退烧药市场

  • Ibuprofen
  • 乙酰胺酚

第十章 依给药途径分類的婴幼儿退烧药市场

  • 口服
  • 直肠给药

第十一章 婴幼儿退烧药市场（依通路划分）

  • 离线
  • 在线的
    • 电子商务平台
    • 公司网站

第十二章：婴幼儿退烧药市场区域分析

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 婴幼儿退烧药市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国婴幼儿退烧药市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国婴幼儿退烧药市场

16. 中国：婴幼儿退烧药市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Procter & Gamble Company
  • Reckitt Benckiser Group PLC
  • Sanofi SA
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Cadila
Product Code: MRR-7B550E008D9C

The Antipyretic Medicine for Infants & Young Children Market was valued at USD 488.97 million in 2025 and is projected to grow to USD 510.70 million in 2026, with a CAGR of 5.67%, reaching USD 719.77 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 488.97 million
Estimated Year [2026] USD 510.70 million
Forecast Year [2032] USD 719.77 million
CAGR (%) 5.67%

A comprehensive orientation to pediatric antipyretic therapy that integrates clinical safety, caregiver behavior, formulation advances, and regulatory dynamics for informed decision-making

The landscape of antipyretic medicine for infants and young children requires a multifaceted introduction that situates clinical considerations, caregiving behavior, regulatory oversight, and supply chain realities within a single narrative. This report opens by clarifying the therapeutic objectives of antipyretic treatment in early childhood, emphasizing safety profiles, dosing accuracy, and caregiver adherence as central themes influencing product design and communication strategies. In addition to clinical practice, the introduction foregrounds the role of formulation science in improving palatability and dosing precision for vulnerable age groups, highlighting how formulation choices influence both caregiver acceptance and adherence to recommended regimens.

Beyond clinical and formulation factors, the opening section also contextualizes broader influences such as evolving pediatric guidance, increased parental expectation for convenient administration, and nascent technological interventions in dosing devices and digital adherence tools. Regulatory and quality assurance considerations are examined in tandem, noting how pharmacovigilance and label clarity shape manufacturer responsibilities and clinician prescribing patterns. By knitting these elements together, the introduction creates a coherent view that prepares readers to explore subsequent sections focused on structural shifts, tariff impacts, segmentation, regional dynamics, competitive behavior, and actionable recommendations that collectively determine strategic imperatives for stakeholders engaged with antipyretic medicines for infants and young children.

Major structural and technological shifts redefining pediatric antipyretic products, distribution, regulation, and caregiver engagement across clinical and commercial dimensions

The antipyretic landscape is undergoing transformative shifts that reconfigure how products are developed, regulated, and distributed for infants and young children. One prominent change is the convergence of formulation innovation with caregiver-centric design; manufacturers are prioritizing easy-to-administer dosage forms and improved palatability while simultaneously investing in packaging and dosing accuracy to reduce administration errors. Alongside these product-level changes, a technology-led transformation is emerging in the form of digital adherence supports and telehealth integration, which alter how caregivers access guidance and how clinicians monitor febrile illness management remotely.

Simultaneously, regulatory scrutiny and harmonization efforts are increasing, prompting companies to standardize labeling clarity and optimize pediatric safety data across jurisdictions. Supply chain modernization is another critical shift, with manufacturers seeking resilient sourcing strategies for active pharmaceutical ingredients, flexible manufacturing arrangements for diverse dosage forms, and distribution agility to meet both traditional pharmacy demand and expanding online channels. Finally, stakeholder expectations around transparency and real-world evidence are rising; payers, clinicians, and caregivers are requesting clearer safety communication and post-market data to inform choices. Taken together, these shifts create a more complex but opportunity-rich environment for stakeholders who can align clinical value with commercial execution and regulatory compliance.

How the 2025 tariff environment reshaped sourcing, manufacturing agility, regulatory compliance, and commercial strategies across pediatric antipyretic supply chains

The introduction of targeted tariff measures by United States authorities in 2025 has created a multilayered set of implications for manufacturers, distributors, and purchasers of antipyretic medicines intended for infants and young children. Tariff-related cost pressures have prompted reassessments of supply chain footprints, leading several companies to explore nearshoring alternatives and to renegotiate supplier agreements to preserve gross margins without compromising product integrity or pediatric safety standards. In parallel, import duty changes have accelerated conversations around sourcing active pharmaceutical ingredients from diversified suppliers and enhancing inventory buffers to mitigate episodic cost volatility.

In trade-sensitive contexts, formulary managers and procurement teams have prioritized procurement strategies that emphasize long-term contractual stability and alternative transport modalities to limit exposure to tariff-driven disruptions. Regulatory compliance teams have also been compelled to align labeling and provenance documentation with customs requirements, increasing administrative workloads and elevating the importance of traceability systems that document origin and manufacturing steps. On the commercial side, inflationary pressures linked to tariffs have shifted promotional and pricing tactics; manufacturers have balanced the need to protect brand equity and maintain accessibility for caregivers by selectively absorbing costs, adjusting pack formats, or reallocating marketing spend toward digital channels where unit economics can be more tightly controlled.

Collectively, the tariff environment of 2025 has underscored the strategic value of flexible manufacturing networks, robust supplier due diligence, and a portfolio approach to channel allocation that preserves product availability for infants and young children while maintaining compliance and financial resilience.

Detailed segmentation-driven insights linking dosage forms, active ingredients, administration routes, distribution channels, and age cohorts to clinical and commercial priorities

Key segmentation insights reveal how product attributes, active ingredients, administration routes, distribution pathways, and age-specific needs shape clinical utility and commercial appeal for antipyretic medicines intended for infants and young children. Based on Dosage Form, the landscape spans Drops, Suspension, Syrup, and Tablet, with each form presenting distinct considerations around dosing precision, caregiver acceptance, and packaging technology. Based on Active Ingredient, the primary agents evaluated are Ibuprofen and Paracetamol, where differential onset of action, dosing intervals, and tolerability profiles influence formulary decisions and caregiver counseling. Based on Administration Route, oral and rectal administration routes serve different clinical and situational roles, informing product positioning especially in post-operative or vomiting scenarios.

Based on Distribution Channel, the channels under review include Offline and Online, with Offline further examined across Hospital and Pharmacy settings and Online further dissected into Ecommerce Platform and Retail Website models; channel strategy affects pricing, promotional dynamics, and access patterns across caregiver cohorts. Based on Age Group, the segmentation differentiates needs among 0-1 Years, 2-5 Years, and 6 Years And Above, with dosing systems, safety data, and flavor profiles tailored to address developmental differences in swallowing ability and weight-based dosing. Together, these segmentation axes illuminate where clinical demands intersect with commercial opportunity, pointing to clear priorities for formulation innovation, distribution optimization, and targeted communication strategies to support both prescribers and caregivers.

How regional regulatory frameworks, distribution architectures, and caregiver preferences across the Americas, Europe Middle East & Africa, and Asia-Pacific shape pediatric antipyretic strategies

Regional dynamics exert a powerful influence over regulatory frameworks, supply chain configurations, and caregiver preferences for antipyretic medicines designed for infants and young children. In the Americas, distribution infrastructures combine sophisticated retail pharmacy networks with growing online fulfillment capacity, and regulatory authorities emphasize pediatric labeling clarity and post-market safety surveillance. These conditions favor products that demonstrate robust pediatric safety data and packaging that supports accurate home dosing, while also enabling partnerships with healthcare institutions for formulary inclusion and professional education.

In Europe, Middle East & Africa, diverse regulatory regimes and wide-ranging healthcare delivery models require flexible commercial strategies that accommodate both centralized reimbursement systems and high-variability private markets. Manufacturers operating across this combined region prioritize harmonized dossier submissions where feasible, and they adapt product portfolios to align with local clinical preferences and supply chain realities. In the Asia-Pacific region, rapid modernization of retail channels, high e-commerce adoption, and strong domestic manufacturing capabilities create opportunities for scalable production and direct-to-consumer engagement. Regional regulators in Asia-Pacific are increasingly focused on pediatric clinical evidence and quality standards, prompting global manufacturers to synchronize clinical data packages and align packaging for multilingual markets. Across all regions, logistical resilience, regulatory alignment, and culturally attuned caregiver communications are decisive factors in product acceptance and long-term success.

Competitive dynamics driven by formulation innovation, pediatric safety credibility, supply chain partnerships, and omnichannel engagement strategies in pediatric antipyretics

Competitive dynamics in the antipyretic segment for infants and young children are determined by a combination of formulation expertise, pediatric safety credibility, supply chain resilience, and channel partnerships. Leading competitors demonstrate a clear focus on dosage precision and caregiver-friendly formats, complemented by targeted investments in clinical evidence and post-market surveillance to sustain professional trust. Differentiation increasingly relies on the ability to couple clinically appropriate active ingredients with packaging innovations that reduce dosing error and improve palatability, thereby enhancing adherence in sensitive age groups.

Strategic alliances and contract manufacturing relationships are central to maintaining supply continuity and achieving scale in preferred dosage forms. At the same time, nimble players exploit online channels and direct-to-consumer education to expand brand reach and foster caregiver loyalty through digital resources and virtual support tools. In procurement-driven settings such as hospitals, competitive advantage accrues to manufacturers who can provide regulatory-compliant product dossiers, flexible packaging configurations, and reliable delivery schedules. Across competitive scenarios, a balanced emphasis on clinical validation, operational excellence, and channel-specific marketing is essential to secure long-term positioning in the pediatric antipyretic category.

Practical strategic actions to align formulation innovation, supply resilience, evidence generation, and channel-specific commercialization for pediatric antipyretic success

Industry leaders seeking to capitalize on opportunities in antipyretic medicines for infants and young children should pursue a set of actionable priorities that align clinical value with commercial and operational excellence. First, invest in formulation and packaging innovations that prioritize dosing accuracy and palatability, and ensure that these enhancements are supported by transparent safety communication and caregiver education materials. Second, strengthen supplier diversification and flexible manufacturing arrangements to reduce exposure to tariff-driven or trade-disruption risks, while enhancing traceability and documentation for regulatory compliance.

Third, develop differentiated channel strategies that reflect the distinct behaviors of Offline and Online endpoints; hospitals and pharmacies demand consistent supply and regulatory rigor, while ecommerce platforms and retail websites require strong digital merchandising and consumer education. Fourth, advance pediatric evidence generation and real-world safety monitoring to build clinician confidence and to inform label clarity and patient counseling tools. Finally, cultivate cross-functional capabilities that integrate regulatory affairs, supply chain management, and commercial analytics so that product launches and lifecycle decisions are executed with operational precision and strategic foresight. Collectively, these measures will support resilient growth while maintaining the highest standards of pediatric safety and caregiver trust.

A robust mixed-methods research approach combining expert interviews, clinical literature synthesis, segmentation analysis, and supply chain scenario evaluation for rigorous insights

The research methodology underpinning this report combines qualitative and quantitative techniques designed to produce rigorous, validated insights into pediatric antipyretic dynamics while respecting clinical and regulatory constraints. Primary research involved structured interviews and consultations with pediatric clinicians, formulation scientists, procurement leads, and channel managers to capture frontline perspectives on dosing practices, product selection criteria, and logistical challenges. This was complemented by secondary source synthesis, which triangulated public regulatory guidelines, product monographs, and clinical literature to ensure alignment with current best practices and safety standards.

Analytical approaches incorporated segmentation analysis across dosage forms, active ingredients, administration routes, distribution channels, and age cohorts to identify differential demand drivers and clinical requirements. Supply chain assessments used scenario analysis to evaluate sourcing resilience and tariff sensitivity, while competitive landscape review applied capability mapping to highlight areas of differentiation among manufacturers and distributors. Throughout the methodology, data quality controls were applied via cross-validation with subject-matter experts and reconciliation of divergent findings, ensuring that the resulting insights are robust, actionable, and reflective of contemporary industry realities.

Synthesis of clinical, operational, and regional imperatives highlighting strategies to secure pediatric safety, supply continuity, and commercial differentiation in antipyretics

In conclusion, the antipyretic segment for infants and young children is characterized by an intersection of clinical imperatives, caregiver expectations, regulatory oversight, and evolving distribution models. Product success hinges on a clear alignment between pediatric safety evidence and practical dosing solutions that caregivers can administer reliably. Concurrently, supply chain resilience and tariff-aware sourcing strategies have become core strategic priorities that influence product availability and commercial flexibility. Regional nuances further color the competitive landscape, requiring tailored regulatory approaches and channel strategies adapted to local healthcare systems and consumer behaviors.

Looking ahead, manufacturers and stakeholders who integrate formulation innovation, rigorous pediatric evidence, and channel-appropriate commercialization will be best positioned to meet caregiver needs while navigating policy and trade complexities. By combining operational agility with clear communication and clinical stewardship, organizations can both safeguard access for vulnerable populations and create defensible differentiation in a crowded therapeutic category. The synthesis presented here supports strategic planning, product lifecycle decisions, and partnership formation that collectively enhance the quality and accessibility of antipyretic care for infants and young children.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antipyretic Medicine for Infants & Young Children Market, by Dosage Form

  • 8.1. Drops
  • 8.2. Suspension
  • 8.3. Syrup
  • 8.4. Tablet

9. Antipyretic Medicine for Infants & Young Children Market, by Active Ingredient

  • 9.1. Ibuprofen
  • 9.2. Paracetamol

10. Antipyretic Medicine for Infants & Young Children Market, by Administration Route

  • 10.1. Oral
  • 10.2. Rectal

11. Antipyretic Medicine for Infants & Young Children Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online
    • 11.2.1. eCommerce Platform
    • 11.2.2. Company Website

12. Antipyretic Medicine for Infants & Young Children Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antipyretic Medicine for Infants & Young Children Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antipyretic Medicine for Infants & Young Children Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Antipyretic Medicine for Infants & Young Children Market

16. China Antipyretic Medicine for Infants & Young Children Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AstraZeneca PLC
  • 17.7. Aurobindo Pharma Limited
  • 17.8. Bayer AG
  • 17.9. Cipla Limited
  • 17.10. Dr. Reddy's Laboratories Ltd.
  • 17.11. GlaxoSmithKline plc
  • 17.12. Glenmark Pharmaceuticals Ltd.
  • 17.13. Johnson & Johnson
  • 17.14. Lupin Limited
  • 17.15. Merck & Co., Inc.
  • 17.16. Mylan N.V.
  • 17.17. Novartis AG
  • 17.18. Perrigo Company plc
  • 17.19. Pfizer Inc.
  • 17.20. Procter & Gamble Company
  • 17.21. Reckitt Benckiser Group PLC
  • 17.22. Sanofi S.A.
  • 17.23. Strides Pharma Science Limited
  • 17.24. Sun Pharmaceutical Industries Ltd.
  • 17.25. Takeda Pharmaceutical Company Limited
  • 17.26. Teva Pharmaceutical Industries Ltd.
  • 17.27. Torrent Pharmaceuticals Ltd.
  • 17.28. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DROPS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DROPS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY SYRUP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY SYRUP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY PARACETAMOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY PARACETAMOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY PARACETAMOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY RECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY RECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY RECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ECOMMERCE PLATFORM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ECOMMERCE PLATFORM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ECOMMERCE PLATFORM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COMPANY WEBSITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COMPANY WEBSITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COMPANY WEBSITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 99. GCC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 101. GCC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 102. GCC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 103. GCC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GCC ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 117. G7 ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 119. G7 ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 120. G7 ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 121. G7 ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. G7 ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 123. NATO ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 125. NATO ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 126. NATO ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 127. NATO ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. NATO ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA ANTIPYRETIC MEDICINE FOR INFANTS & YOUNG CHILDREN MARKET SIZE, BY ONLINE, 2018-2032 (USD MILLION)